Search
Search Results
-
The Evaluation of Drug Innovativeness in Italy: Key Determinants and Internal Consistency
BackgroundInnovative medicines are provided with dedicated funds and immediate market access in Italy. Innovativeness evaluation considers unmet...
-
A systematic review on reporting quality of economic evaluations for negotiated glucose-lowering drugs in China national reimbursement drug list
BackgroundThis study aimed to examine the reporting quality of existing economic evaluations for negotiated glucose-lowering drugs (GLDs) included in...
-
Map** digital health ecosystems in Africa in the context of endemic infectious and non-communicable diseases
Investments in digital health technologies such as artificial intelligence, wearable devices, and telemedicine may support Africa achieve United...
-
Cost-effectiveness of Finerenone in Addition to Standard of Care for Patients with Chronic Kidney Disease and Type 2 Diabetes in China
IntroductionAdding finerenone to current standard of care (SoC), as recommended by Chinese guidelines, has shown substantial benefit in delaying...
-
Successes and challenges of China’s health care reform: a four-decade perspective spanning 1985—2023
Chinese health system remains the crucial one for understanding the wider healthcare landscape across the Global South and in particular the leading...
-
Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multi‐stakeholder, international workshop
BackgroundIt is increasingly common for two or more treatments for cancer to be combined as a single regimen. Determining value and appropriate...
-
How Managed Entry Agreements can improve allocation in the public health system: a mechanism design approach
The process of introducing a new health technology into a healthcare system is characterized by uncertainty and risk for those...
-
Determinants of Orphan Drug Prices in Germany
Background and ObjectiveLegislation introduced in 2011 in Germany has instituted an early benefit assessment of newly licensed pharmaceuticals with a...
-
Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry
ObjectiveSodium–glucose cotransporter 2 inhibitors (SGLT2i) have been shown to reduce the risk of cardiovascular complications, which largely drive...
-
Value-based pricing for advanced therapy medicinal products: emerging affordability solutions
The emergence of advanced therapy medicinal products (ATMPs), a disruptive class of health technologies, is generating important challenges in terms...
-
Assessing the performance of health technology assessment (HTA) agencies: develo** a multi-country, multi-stakeholder, and multi-dimensional framework to explore mechanisms of impact
BackgroundHealth technology assessment (HTA) agencies have an important role to play in managing the rising demands on health systems. However,...
-
Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
BackgroundThe anti-fibrotic medications nintedanib and pirfenidone were approved in the United States for use in patients with idiopathic pulmonary...
-
Evolving Trends in Consumption of Direct Oral Anticoagulants in 65 Countries/Regions from 2008 to 2019
BackgroundDirect oral anticoagulants (DOACs) have been increasingly utilised over warfarin. However, little is known about the relative consumption...
-
Strengthening access to cancer medicines for children in East Africa: policy options to enhance medicine procurement, forecasting, and regulations
Gaps in access to quality essential medicines remain a major impediment to the effective care of children with cancer in low-and middle-income...
-
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requiring a PASS would be more likely to be reimbursed in Spain
BackgroundThe present study aims to assess clinical and regulatory variables that would influence pricing and reimbursement (P&R) decisions for...
-
The impact of “4 + 7” volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis
BackgroundIn 2019, Chinese government launched a nationwide volume-based drug procurement aiming at reducing drug prices and saving drug costs...
-
Antipsychotics and Identity: The Adverse Effect No One is Talking About
People who take antipsychotics, and people who are prescribed antipsychotics without taking them, experience effects which are not frequently...
-
Estimation of the value of curative therapies in oncology: a willingness-to-pay study in China
The objective of this study was to estimate the willingness to pay (WTP) per quality-adjusted life year (QALY) among people with malignancies in...
-
Translating Research to Policy: Setting Provider Payment Rates for Strategic Purchasing under India's National Publicly Financed Health Insurance Scheme
BackgroundIn 2018, the Government of India launched Ayushman Bharat Pradhan Mantri-Jan Aarogya Yojana (AB PM-JAY), a large tax-funded health...
